MYCN and neoplasm: The response of chemo-naïve IMR-32 cells to SN22 was compared to that of the BE(2)C cell line, which originates from a MYCN-amplified NB tumor with a loss-of-function mutation in p53 acquired after a non-curative treatment [44].